Institut Bergonie

Phase [desc]	Trial	Trial Status	Site Status	Drug	NCT#
2	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	Active	Regorafenib (SDH)	NCT02638766
2	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	Recruiting	Active	Imatinib	NCT05009927
2	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	Completed	Closed	Lenvatinib	NCT04193553
2	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	Recruiting	Active	Imatinib + Atezolizumab	NCT05152472
1	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers	Completed	Closed	Masitinib, (AB1010)
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237